JP2011526892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526892A5 JP2011526892A5 JP2011516339A JP2011516339A JP2011526892A5 JP 2011526892 A5 JP2011526892 A5 JP 2011526892A5 JP 2011516339 A JP2011516339 A JP 2011516339A JP 2011516339 A JP2011516339 A JP 2011516339A JP 2011526892 A5 JP2011526892 A5 JP 2011526892A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 108091008605 VEGF receptors Proteins 0.000 claims 5
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 5
- 230000001413 cellular effect Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 4
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 claims 3
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- JLTPSDHKZGWXTD-UHFFFAOYSA-N 2-[6-(dicyanomethylidene)naphthalen-2-ylidene]propanedinitrile Chemical compound N#CC(C#N)=C1C=CC2=CC(=C(C#N)C#N)C=CC2=C1 JLTPSDHKZGWXTD-UHFFFAOYSA-N 0.000 claims 1
- 206010000050 Abdominal adhesions Diseases 0.000 claims 1
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims 1
- 101710161969 Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003732 Cat-scratch disease Diseases 0.000 claims 1
- 206010011017 Corneal graft rejection Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 101150052863 THY1 gene Proteins 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- 208000013058 Weber syndrome Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000007293 brain stem infarction Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 208000031209 hemophilic arthropathy Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002390 hyperplastic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000038015 macular disease Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13360708P | 2008-06-30 | 2008-06-30 | |
| US61/133,607 | 2008-06-30 | ||
| AU2008903349 | 2008-06-30 | ||
| AU2008903349A AU2008903349A0 (en) | 2008-06-30 | Treatment of eye diseases and excessive neovascularization using combined therapy | |
| PCT/US2009/003902 WO2010005527A1 (en) | 2008-06-30 | 2009-06-29 | Treatment of eye diseases and excessive neovascularization using a combined therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138345A Division JP2015038059A (ja) | 2008-06-30 | 2014-07-04 | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526892A JP2011526892A (ja) | 2011-10-20 |
| JP2011526892A5 true JP2011526892A5 (https=) | 2012-08-09 |
Family
ID=41507350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516339A Withdrawn JP2011526892A (ja) | 2008-06-30 | 2009-06-29 | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
| JP2014138345A Pending JP2015038059A (ja) | 2008-06-30 | 2014-07-04 | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138345A Pending JP2015038059A (ja) | 2008-06-30 | 2014-07-04 | 併用療法を使用した眼疾患及び過剰血管新生の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110200612A1 (https=) |
| EP (1) | EP2294184A4 (https=) |
| JP (2) | JP2011526892A (https=) |
| KR (1) | KR20110036101A (https=) |
| CN (1) | CN102076844B (https=) |
| AU (2) | AU2009269149B2 (https=) |
| CA (1) | CA2729303A1 (https=) |
| SG (1) | SG10201510586PA (https=) |
| WO (1) | WO2010005527A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| WO2013003594A2 (en) * | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US8083787B2 (en) | 2005-07-18 | 2011-12-27 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| EP2538965B1 (en) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| KR101786862B1 (ko) * | 2011-07-04 | 2017-10-18 | 메소블라스트, 아이엔씨. | 류마티즘성 질환을 치료 또는 예방하는 방법 |
| AU2012279995C1 (en) | 2011-07-06 | 2019-10-24 | Cell Therapy Limited | Progenitor cells of mesodermal lineage |
| FR2983478B1 (fr) | 2011-12-01 | 2013-11-15 | Arkema France | Procede de preparation d'aminoacide comprenant une etape d'hydroformylation d'un nitrile gras insature |
| CN103505727A (zh) * | 2012-06-28 | 2014-01-15 | 中国科学院生物物理研究所 | 靶向作为vegfr-2共受体cd146的新功能在抗肿瘤血管新生治疗中的应用 |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| SG11201504340YA (en) * | 2012-12-12 | 2015-07-30 | Mesoblast Inc | Treatment of diseases of endothelial dysfunction and inflammation |
| ES2821002T3 (es) | 2013-04-30 | 2021-04-23 | Alcon Inc | Sistemas para el tratamiento de enfermedades del ojo |
| US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| US10543270B2 (en) * | 2013-12-18 | 2020-01-28 | Csl Limited | Methods of treating wounds in a diabetic subject |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| US10624930B2 (en) * | 2014-06-10 | 2020-04-21 | Mesoblast International Sarl | Treatment of immune disorders |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| KR101880790B1 (ko) * | 2015-04-07 | 2018-08-16 | 서강대학교산학협력단 | 망막질병 치료를 위한 효과 지속성(Long-term) siRNA 기반 나노메디슨 및 이의 제조방법 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US20170253854A1 (en) * | 2016-03-02 | 2017-09-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of Adipose-Derived Stem Cells for Glaucoma Treatment |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
| CN109526229B (zh) | 2016-07-08 | 2022-06-03 | Tak循环株式会社 | 筛选疾病的预防或治疗剂的方法、及用于制造该制剂的应用 |
| JP7106788B2 (ja) * | 2016-07-08 | 2022-07-27 | ＴＡＫ－Ｃｉｒｃｕｌａｔｏｒ株式会社 | Ｍｅｘ３ｂ遺伝子の発現を抑制する核酸、ｍｅｘ３ｂ遺伝子発現抑制剤、ｍｅｘ３ｂ遺伝子発現を抑制する方法及びｍｅｘ３ｂ遺伝子発現に起因する疾病の予防又は治療剤 |
| RU2019103384A (ru) * | 2016-07-26 | 2020-08-26 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Опосредуемая вектором иммунологическая толерантность глаз |
| WO2018092769A1 (ja) | 2016-11-15 | 2018-05-24 | 株式会社カネカ | 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN107043699B (zh) * | 2017-04-25 | 2023-04-07 | 徐子雁 | 一种低能量激光诱导间充质干细胞血管化的试剂盒 |
| US20200206077A1 (en) * | 2017-06-26 | 2020-07-02 | Amd-Opti, Llc | Autologous stem cell therapies for treatment of eye disease |
| CN119033819A (zh) | 2017-11-22 | 2024-11-29 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| WO2019132026A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| AU2020204809A1 (en) * | 2019-01-03 | 2021-07-29 | Mesoblast International Sàrl | Method for improving visual acuity |
| WO2020251020A1 (ja) | 2019-06-14 | 2020-12-17 | 株式会社カネカ | 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法 |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3089815A (en) | 1951-10-11 | 1963-05-14 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4983393A (en) | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| DE69530914T2 (de) | 1994-02-17 | 2004-03-11 | New York Blood Center, Inc. | Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
| US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US20030216335A1 (en) | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| KR100567649B1 (ko) | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| US6162428A (en) | 1997-02-12 | 2000-12-19 | Layton Bioscience, Inc. | hNT-neuron human neuronal cells to replace ganglion cells |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999040118A1 (en) | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Antibodies against human vegf receptor kdr |
| WO1999049029A1 (en) | 1998-03-20 | 1999-09-30 | Benitec Australia Ltd | Control of gene expression |
| NZ507093A (en) | 1998-04-08 | 2003-08-29 | Commw Scient Ind Res Org | Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant |
| US6284245B1 (en) | 1998-08-25 | 2001-09-04 | Diacrin, Inc. | Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders |
| DE69930872T8 (de) | 1998-12-21 | 2007-05-03 | Ludwig Institute For Cancer Research | Antikörper gegen verkürzten vegf-d und deren verwendungen |
| AU757680B2 (en) | 1999-07-01 | 2003-02-27 | Taisho Pharmaceutical Co., Ltd. | Aminobenzoic acid derivatives |
| AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
| AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| WO2001066127A1 (en) | 1999-12-21 | 2001-09-13 | Korea Green Cross Corporation | Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis |
| EP1248642A4 (en) | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF |
| US6733755B2 (en) | 2000-02-04 | 2004-05-11 | Supratek Pharma, Inc. | Ligand for vascular endothelial growth factor receptor |
| PT1254138E (pt) | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| JP2004513676A (ja) | 2000-06-22 | 2004-05-13 | オースティン，サム，エル | 生体接着剤組成物及びその製造と使用 |
| WO2002012226A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| US20030186920A1 (en) | 2000-10-13 | 2003-10-02 | Sirois Martin G. | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
| JP2004517631A (ja) | 2001-01-17 | 2004-06-17 | ヨウン メー パク | クエルセチンにより血管内皮成長因子及びエリスロポエチンの遺伝子発現を阻害する方法 |
| AU2002338313A1 (en) | 2001-04-06 | 2002-10-21 | Maxygen Holdings Ltd. | Single chain dimeric polypeptides derived from the vegf family |
| AU2002252631A1 (en) | 2001-04-13 | 2002-10-28 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050054596A1 (en) | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050222066A1 (en) | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| CA2461290C (en) * | 2001-09-24 | 2014-11-25 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
| US6942655B2 (en) | 2001-11-13 | 2005-09-13 | Minu, Llc | Method to treat age-related macular degeneration |
| US20040138163A1 (en) | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003072064A2 (en) * | 2002-02-28 | 2003-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regulating adipogenesis |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US20040121955A1 (en) | 2002-04-01 | 2004-06-24 | Mulligan-Kehoe Mary Jo | Methods for modulating angiogenesis |
| US20040005671A1 (en) | 2002-05-17 | 2004-01-08 | Amrad Operations Pty Ltd. | Immunointeractive molecules |
| WO2004033635A2 (en) | 2002-10-04 | 2004-04-22 | Tissuetech, Inc. | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
| CA2407755A1 (en) * | 2002-10-11 | 2004-04-11 | The Hospital For Sick Children | Inhibition of vegf secretion |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| BRPI0409230A (pt) | 2003-04-03 | 2006-03-28 | Pfizer | formas de dosagem compreendendo ag013736 |
| US20040198798A1 (en) | 2003-04-07 | 2004-10-07 | Park Jong-Wan | Method for inhibiting tumor angiogenesis and tumor growth |
| WO2005007828A2 (en) | 2003-07-14 | 2005-01-27 | Prolx Pharmaceuticals, Inc. | Regulation of hif protein levels via deubiquitination pathways |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| US7850959B2 (en) * | 2003-10-10 | 2010-12-14 | Beth Israel Deaconess Medical Center | Methods and compositions for treating conditions involving abnormal angiogenesis |
| GB0328021D0 (en) | 2003-12-03 | 2004-01-07 | Inst Of Ophthalmology | Method |
| AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7150970B2 (en) | 2004-08-02 | 2006-12-19 | University Of Iowa Research Foundation | Methods of inhibiting VEGF-C |
| EP1786477A2 (en) * | 2004-08-17 | 2007-05-23 | Prolx Pharmaceuticals Corp. | Method of preselection patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy |
| US20060110364A1 (en) | 2004-08-20 | 2006-05-25 | Ludwig Institute For Cancer Research | Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors |
| CA2866468C (en) | 2004-09-24 | 2019-09-03 | Mesoblast, Inc. | Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| AU2005306325A1 (en) * | 2004-11-22 | 2006-05-26 | King Pharmaceuticals Research & Development Inc. | Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists |
| CA2598029A1 (en) * | 2005-02-24 | 2006-10-05 | The Scripps Research Institute | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
| WO2006108229A1 (en) | 2005-04-12 | 2006-10-19 | Angioblast Systems, Inc. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
| US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| WO2007013704A1 (en) | 2005-07-27 | 2007-02-01 | Juseong College Industry Academy Cooperation Group | Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same |
| CA2627873A1 (en) | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
| GB0523810D0 (en) | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| CN100371444C (zh) | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | 一种抑制VEGF表达的siRNA及其应用 |
| CN100374573C (zh) | 2006-04-14 | 2008-03-12 | 中国医学科学院医药生物技术研究所 | 一种可稳定表达VEGF shRNA的载体pCD-VEGF |
| US20080089868A1 (en) | 2006-04-27 | 2008-04-17 | The Research Foundation Of State University Of New York | Retinal stem cell compositions and methods for preparing and using same |
| WO2007130060A2 (en) | 2006-05-03 | 2007-11-15 | Schepens Eye Research | Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues |
| US9598673B2 (en) * | 2006-05-19 | 2017-03-21 | Creative Medical Health | Treatment of disc degenerative disease |
| WO2007140534A1 (en) | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
| KR100787131B1 (ko) | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 |
| JP6041456B2 (ja) * | 2006-07-12 | 2016-12-07 | メゾブラスト，インコーポレーテッド | 過剰新生血管形成の治療 |
| CN101516902B (zh) * | 2006-07-31 | 2012-08-08 | 脉管生物生长有限公司 | 多肽和其编码多聚核苷酸及它们在治疗缺血相关医学病症中的应用 |
| WO2008031835A2 (en) | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
| WO2008045576A2 (en) | 2006-10-12 | 2008-04-17 | Yijia Liu | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
| EP2073802A1 (en) * | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| CA2666709A1 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| WO2008098299A1 (en) * | 2007-02-14 | 2008-08-21 | Opto Global Holdings Pty Ltd | Methods and systems of treating age-related macular degeneration |
| US8983570B2 (en) * | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
| US7867724B2 (en) * | 2007-11-05 | 2011-01-11 | California Institute Of Technology | Compositions and method of treating hypoxia-associated diseases |
| MX2010010068A (es) * | 2008-03-11 | 2010-10-04 | Univ North Carolina | Composiciones angiostaticas que comprenden polipeptidos de tirosil-acido ribonucleico de transferencia sintetasa truncado y metodos de uso de las mismas. |
| WO2010068794A2 (en) * | 2008-12-10 | 2010-06-17 | The General Hospital Corporation | Hif inhibitors and use thereof |
| BR112013000341A2 (pt) * | 2010-07-07 | 2017-09-26 | Tubitak | estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr) |
-
2009
- 2009-06-29 JP JP2011516339A patent/JP2011526892A/ja not_active Withdrawn
- 2009-06-29 AU AU2009269149A patent/AU2009269149B2/en not_active Ceased
- 2009-06-29 US US13/002,229 patent/US20110200612A1/en not_active Abandoned
- 2009-06-29 KR KR1020117002350A patent/KR20110036101A/ko not_active Ceased
- 2009-06-29 EP EP09794792A patent/EP2294184A4/en not_active Withdrawn
- 2009-06-29 SG SG10201510586PA patent/SG10201510586PA/en unknown
- 2009-06-29 CN CN2009801249790A patent/CN102076844B/zh not_active Expired - Fee Related
- 2009-06-29 CA CA2729303A patent/CA2729303A1/en not_active Abandoned
- 2009-06-29 WO PCT/US2009/003902 patent/WO2010005527A1/en not_active Ceased
-
2014
- 2014-07-04 JP JP2014138345A patent/JP2015038059A/ja active Pending
-
2016
- 2016-06-14 AU AU2016203973A patent/AU2016203973A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526892A5 (https=) | ||
| JP7813931B2 (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| Demoulin et al. | PDGF receptor signaling networks in normal and cancer cells | |
| Liu et al. | Targeting neuropilin-1 interactions is a promising anti-tumor strategy | |
| Tate et al. | Biology of angiogenesis and invasion in glioma | |
| Rosenbloom et al. | Human fibrotic diseases: current challenges in fibrosis research | |
| Wang et al. | CXCR7 targeting and its major disease relevance | |
| Liu et al. | The antitumor effect of gene-engineered exosomes in the treatment of brain metastasis of breast cancer | |
| Campanholle et al. | Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis | |
| Zhang et al. | Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-κB pathway activation | |
| Shao et al. | Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization | |
| Armas-López et al. | The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy | |
| Guyot et al. | VEGF splicing and the role of VEGF splice variants: from physiological-pathological conditions to specific pre-mRNA splicing | |
| JP2021529187A (ja) | Ｎｌｒｐモジュレータ | |
| UA123905C2 (uk) | Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53 | |
| JP2022508751A (ja) | Ｐｆｋｆｂ３阻害剤とその使用 | |
| JP2013509874A (ja) | 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法 | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| Fu et al. | Brain pericyte biology: From physiopathological mechanisms to potential therapeutic applications in ischemic stroke | |
| Liang et al. | A new antitumor direction: tumor-specific endothelial cells | |
| Yousaf et al. | Hypoxia-inducible factor stabilizers: a new avenue for reducing BP while helping hemoglobin? | |
| JP2022518260A (ja) | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 | |
| Pu et al. | Microvascular targets for anti-fibrotic therapeutics | |
| JP2021529186A (ja) | Ｎｌｒｐ調節剤 | |
| US20110123534A1 (en) | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |